ANT2 Protein
Overview
ANT2 (Adenine Nucleotide Translocator 2), encoded by the SLC25A5 gene, is a mitochondrial membrane protein belonging to the solute carrier family 25 (SLC25A) of transporters. Also known as ADP/ATP translocase 2, ANT2 is one of four adenine nucleotide translocator isoforms (ANT1-ANT4) that mediate the exchange of adenosine nucleotides across the inner mitochondrial membrane. ANT2 is highly expressed in tissues with elevated metabolic demands, particularly in the brain, heart, and skeletal muscle. The protein exists as part of the ATP/ADP antiporter system, which is essential for maintaining the mitochondrial pool of ATP available for cellular energy production. Mutations in the SLC25A5 gene have been associated with various neurodegenerative conditions, highlighting ANT2's critical role in neuronal energy metabolism.
Function/Biology
ANT2 functions as an antiporter, transporting ATP out of the mitochondrial matrix in exchange for ADP entry from the cytoplasm. This bidirectional nucleotide exchange mechanism is driven by the electrochemical gradient established across the inner mitochondrial membrane. The protein maintains cellular energy homeostasis by ensuring continuous regeneration of cytoplasmic ATP pools while facilitating oxidative phosphorylation within mitochondria. ANT2 contains six transmembrane domains and possesses specific nucleotide-binding sites that exhibit high selectivity for adenine nucleotides.
...ANT2 Protein
Overview
ANT2 (Adenine Nucleotide Translocator 2), encoded by the SLC25A5 gene, is a mitochondrial membrane protein belonging to the solute carrier family 25 (SLC25A) of transporters. Also known as ADP/ATP translocase 2, ANT2 is one of four adenine nucleotide translocator isoforms (ANT1-ANT4) that mediate the exchange of adenosine nucleotides across the inner mitochondrial membrane. ANT2 is highly expressed in tissues with elevated metabolic demands, particularly in the brain, heart, and skeletal muscle. The protein exists as part of the ATP/ADP antiporter system, which is essential for maintaining the mitochondrial pool of ATP available for cellular energy production. Mutations in the SLC25A5 gene have been associated with various neurodegenerative conditions, highlighting ANT2's critical role in neuronal energy metabolism.
Function/Biology
ANT2 functions as an antiporter, transporting ATP out of the mitochondrial matrix in exchange for ADP entry from the cytoplasm. This bidirectional nucleotide exchange mechanism is driven by the electrochemical gradient established across the inner mitochondrial membrane. The protein maintains cellular energy homeostasis by ensuring continuous regeneration of cytoplasmic ATP pools while facilitating oxidative phosphorylation within mitochondria. ANT2 contains six transmembrane domains and possesses specific nucleotide-binding sites that exhibit high selectivity for adenine nucleotides.
Unlike ANT1, which is primarily expressed in skeletal muscle and heart, ANT2 maintains constitutive expression in most tissues, including the central nervous system. This differential expression pattern suggests ANT2 plays a housekeeping role in basal ATP/ADP exchange across diverse cell types. The protein's activity is regulated by various factors including the adenine nucleotide/phosphate ratio, membrane potential, and interaction with regulatory proteins such as carboxyatractyloside (CAT) and bongkrekic acid (BKA), which serve as experimental modulators of ANT function.
Role in Neurodegeneration
ANT2 dysfunction contributes to multiple neurodegenerative pathways through compromised mitochondrial energy production. The brain consumes approximately 20% of the body's ATP despite representing only 2% of body mass, making neurons exceptionally vulnerable to defects in ATP/ADP exchange. Impaired ANT2 function reduces the efficiency of ATP regeneration, leading to energy deficit in neuronal soma and axons. This energy depletion triggers calcium dysregulation, accumulation of reactive oxygen species (ROS), and activation of apoptotic pathways characteristic of neurodegeneration.
ANT2 dysfunction has been implicated in Alzheimer's disease pathology, where mitochondrial dysfunction and reduced ATP availability exacerbate amyloid-β accumulation and tau phosphorylation. Similarly, in Parkinson's disease, compromised ANT2-mediated ATP/ADP exchange contributes to dopaminergic neuron vulnerability to α-synuclein toxicity. In amyotrophic lateral sclerosis (ALS), ANT2 impairment reduces the energy supply to motor neuron axons, accelerating degeneration. The protein's role in maintaining cellular energetics directly impacts the capacity of neurons to sustain protein synthesis, maintain ion gradients, and operate ATP-dependent protein quality control mechanisms including the ubiquitin-proteasome system and autophagy.
Molecular Mechanisms
ANT2-mediated neurodegeneration operates through interconnected mechanisms: (1) Bioenergetic failure: reduced ATP/ADP exchange capacity decreases accessible ATP pools, limiting ATP-dependent processes; (2) Calcium dysregulation: energy depletion impairs Na+/Ca2+ exchangers and SERCA pumps, disrupting calcium homeostasis; (3) Oxidative stress amplification: mitochondrial dysfunction increases ROS production, which damages lipids, proteins, and DNA; (4) Autophagy impairment: reduced ATP availability compromises autophagosome formation and degradation, promoting accumulation of misfolded proteins and aggregates; (5) Apoptosis activation: sustained energy deficit triggers intrinsic apoptotic pathways through mitochondrial outer membrane permeabilization (MOMP).
ANT2 interacts functionally with other mitochondrial proteins including the voltage-dependent anion channel (VDAC), the phosphate carrier (PIC), and components of the permeability transition pore complex (PTPC). These associations modulate ANT2 accessibility and efficiency.
Clinical/Research Significance
ANT2 mutations cause rare mitochondrial disorders presenting with neurological manifestations including developmental delay, progressive neurodegeneration, and metabolic encephalopathy. Research into ANT2 function has revealed potential therapeutic targets: modulating ANT2 expression, enhancing its catalytic efficiency, or protecting it from oxidative damage may preserve neuronal energy metabolism. Pharmacological approaches targeting ANT2 regulation show promise in preclinical models of Alzheimer's and Parkinson's diseases.
AlphaFold Structure
AlphaFold DB provides a predicted structure for SLC25A5 / UniProt P05141 (model version 6): https://alphafold.ebi.ac.uk/entry/P05141.
AlphaFold reports a mean pLDDT confidence score of 91.75, indicating very high average confidence.
InterPro annotations highlight Mitochondrial carrier protein family (11-24); ADP/ATP carrier protein, eukaryotic type family (4-297); Mitochondrial carrier protein, transmembrane region repeat (6-100).
PDB coordinates: https://alphafold.ebi.ac.uk/files/AF-P05141-F1-model_v6.pdb mmCIF coordinates: https://alphafold.ebi.ac.uk/files/AF-P05141-F1-model_v6.cif.
Use the prediction as structural context for target assessment; local low-pLDDT segments may reflect disorder, flexible linkers, or unresolved domain orientation rather than a stable fold.